Celltrion Reveals Positive Clinical Trial Data for Biosimilar Adalimumab June 3, 2021 Auto Bot News 0 Celltrion Healthcare has revealed positive one-year results from a Phase III trial comparing biosimilar adalimumab, Yuflyma, with the reference adalimumab in patients with rheumatoid arthritis.